The global health response to the Ebola outbreak in East Africa shows measurable progress since the 2014-2016 crisis, with $61 million committed by CEPI to develop vaccines against the Bundibugyo species. This represents a significant market shift toward proactive funding for pandemic preparedness, though the response remains hampered by delayed identification of the virus and supply chain disruptions.

The creation of the Coalition for Epidemic Preparedness Innovation has fundamentally changed how pharmaceutical companies approach vaccine development, with advance production mechanisms now in place to deploy experimental vaccines immediately after clinical trials. This shift creates new market opportunities for biotech firms while reducing financial risk through international funding pools that share development costs across multiple stakeholders.

Despite improvements in coordination, funding gaps persist as the Bundibugyo response costs $518 million yet only 1% of global R&D spending targets emerging infectious diseases. US withdrawal from WHO and reduced NIH funding threatens to undermine these advances, leaving the private sector as the primary investor in pandemic preparedness with uncertain returns.